美国肿瘤肾脏病学会:癌症合并慢性肾脏病患者贫血管理立场声明
该立场声明由美国肿瘤肾脏病学会以共识为基础制定,针对慢性肾脏病合并癌症患者的贫血,总结其病理生理与临床影响,提出实用诊断路径,并就铁剂、促红细胞生成素刺激剂和红细胞输注阈值给出共识推荐,同时讨论缺氧诱导因子脯氨酰羟化酶抑制剂等新兴治疗。
要点
- 慢性肾脏病与恶性肿瘤共存时贫血机制重叠,诊断存在不确定性。
- 不能简单套用单纯慢性肾脏病或肿瘤贫血指南,需个体化决策。
- 铁剂、促红细胞生成素刺激剂和输血阈值是主要治疗不确定点。
核心结论
- 该共识为慢性肾脏病合并癌症患者的贫血管理提供统一、以患者为中心的框架,支持平衡疗效、安全性与治疗目标的个体化决策。
研究设计与样本
- 美国肿瘤肾脏病学会基于共识制定的立场声明,方法为总结病理生理与临床影响、概述诊断路径并形成共识推荐。
主要发现
- 慢性肾脏病合并恶性肿瘤时,促红细胞生成素减少、炎症与铁调素驱动的铁限制性红细胞生成、抗癌治疗骨髓抑制、骨髓浸润、出血和营养缺乏等机制重叠,造成诊断不确定。
- 声明强调了铁剂、促红细胞生成素刺激剂和红细胞输注阈值方面的关键治疗不确定性。
临床怎么用
- 临床应认识慢性肾脏病合并癌症患者贫血机制的重叠性,采用实用诊断路径并个体化选择铁剂、促红细胞生成素刺激剂或输血。
- 决策需平衡疗效、安全性与患者治疗目标,并关注缺氧诱导因子脯氨酰羟化酶抑制剂等新兴治疗在恶性肿瘤背景下的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anemia is a common complication in patients with chronic kidney disease and cancer and is increasingly observed with declining kidney function. When chronic kidney disease and malignancy coexist, overlapping mechanisms, including reduced erythropoietin production, iron-restricted erythropoiesis driven by inflammation and hepcidin, myelosuppression from anticancer therapy, marrow infiltration, bleeding, and nutritional deficiencies, create diagnostic uncertainty and limit straightforward extrapolation from chronic kidney disease- or oncology-only anemia guidance. In this consensus-based guideline, we summarize the pathophysiology and clinical impact of anemia in patients with concomitant chronic kidney disease and cancer, outline a practical diagnostic approach, and provide consensus recommendations for management. We highlight key therapeutic uncertainties regarding the use of iron therapy, erythropoiesis-stimulating agents, and red blood cell transfusion thresholds, and we discuss emerging therapies, such as hypoxia-inducible factor prolyl hydroxylase inhibitors in the setting of malignancy. This position statement on behalf of the American Society of Onconephrology provides a unified, patient-centered framework to support individualized decision-making that balances efficacy, safety, and goals of care in this increasingly prevalent and complex population.
引用
- Costa E Silva VT, Kanduri SR, Van Doren L, et al. Recommendations for the management of anemia in patients with cancer and chronic kidney disease: a position statement from the American Society of Onconephrology. Kidney Int. 2026. PMID: 42933492. doi:10.1016/j.kint.2026.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。